Who is sponsoring ATLAAST?

ATLAAST is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in ATLAAST?

Interventions: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks.

What is the status of ATLAAST?

ATLAAST is currently COMPLETED.

Last reviewed 2016-09-20 · How we verify

An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension (ATLAAST)

NCT00739596 Phase 4 COMPLETED Results posted

The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 4
Status	COMPLETED
Enrolment	332
Start date	2008-07
Completion	2009-03

Conditions

Hypertension

Interventions

Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks
Amlodipine: 8 weeks

Primary outcomes

Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment — Baseline and 8 weeks
To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.

Countries

United States